MyFinsight
Home
Blog
About
MapLight Therapeutics, Inc. (MPLT)
MapLight Therapeutics, Inc. (MPLT)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$15,926K
Free Cash flow
-$44,892K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities and redemptions of in...
Stock-based compensation expense
Accrued expenses
Others
Negative Cash Flow Breakdown
Purchases of short-term and long...
Accounts payable
Net amortization of premiums and...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-60,192
-60,668
-79,548
-81,604
Depreciation expense
147
162
140
438
Stock-based compensation expense
8,626
9,636
35,521
485
Net amortization of premiums and accretion of discounts on investments
999
814
1,442
660
Common stock issued to neurosolis, inc
0
-
0
496
Non-cash lease expense
217
229
222
644
Loss on disposal of property and equipment
0
-4
0
-7
Prepaid expenses and other assets
-2,846
-2,475
2,329
10,774
Accounts payable
-1,126
-111
893
491
Accrued expenses
5,841
-1,880
1,124
1,775
Operating lease liabilities
-230
-211
-204
-573
Deferred grant earnings
0
-
-1,206
-2,033
Net cash used in operating activities
-44,870
-51,178
-46,829
-91,308
Purchases of short-term and long-term investments
19,773
-
266,177
142,057
Maturities of marketable debt securities
-
-
24,000
61,500
Maturities and redemptions of investments
80,499
67,031
-
-
Purchases of property and equipment
22
24
376
97
Net cash provided by investing activities
60,704
67,007
-242,553
-80,654
Payments of deferred offering costs
0
-
3,894
1,127
Proceeds from issuance of series d redeemable convertible preferred stock, net of issuance costs
-
-
-30
198,870
Proceeds from initial public offering of common stock and private placement, net of underwriting fees
-
-
275,716
-
Proceeds from exercises of stock options
93
-
173
112
Proceeds from exercises of stock options and employee stock purchase plan issuances
-
651
-
-
Proceeds from employee stock purchase plan issuances
650
-
-
-
Payment of employee tax obligations related to vesting of restricted stock units
0
7,502
-
-
Net cash used in financing activities
92
-6,851
271,965
197,855
Increase (decrease) in cash, cash equivalents and restricted cash
15,926
8,978
-17,417
25,893
Cash, cash equivalents, and restricted cash at beginning of period
55,914
46,936
64,353
38,460
Cash, cash equivalents, and restricted cash at end of period
71,840
55,914
46,936
64,353
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities and redemptions
of investments
$80,499K
Proceeds from employee
stock purchase plan...
$650K
Proceeds from exercises
of stock options
$93K
Net cash provided by
investing activities
$60,704K
Net cash used in
financing activities
$92K
Canceled cashflow
$19,795K
Canceled cashflow
$651K
Increase (decrease) in
cash, cash...
$15,926K
Canceled cashflow
$44,870K
Purchases of short-term
and long-term...
$19,773K
Purchases of property and
equipment
$22K
Stock-based compensation
expense
$8,626K
Accrued expenses
$5,841K
Prepaid expenses and
other assets
-$2,846K
Non-cash lease expense
$217K
Depreciation expense
$147K
something is missing
-$651K
Net cash used in
operating activities
-$44,870K
Canceled cashflow
$17,677K
Net loss
-$60,192K
Accounts payable
-$1,126K
Net amortization of
premiums and accretion of...
$999K
Operating lease
liabilities
-$230K
Buy us a coffee